Clinical Trials for Non-Small Cell Lung Cancer

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial enrolls patients with advanced or recurrent non-small cell lung cancer having EGFR mutations and MET amplification, who progressed after osimertinib, to assess the efficacy of capmatinib (a MET inhibitor) and osimertinib with or without ramucirumab (an anti-angiogenic antibody).

ClinicalTrials.gov ID: NCT05642572

An Open-Label Phase I/II Study to Evaluate the Safety and prelimiBasnary Efficacy of Amivantamab and Tepotinib Combination in MET-altered Non-small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced MET-altered non-small cell lung cancer (NSCLC), specifically MET exon 14 skipping alterations or MET gene amplification, and evaluates the safety and efficacy of the combination treatment of amivantamab, a bispecific antibody targeting EGFR and c-MET, and tepotinib, an oral MET inhibitor.

ClinicalTrials.gov ID: NCT06083857

A Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates the efficacy of nivolumab, an immune checkpoint inhibitor targeting the PD-1 receptor, combined with ramucirumab, a VEGFR2 inhibitor, in patients with recurrent, advanced, metastatic non-small cell lung carcinoma who have previously received immunotherapy. It is specifically for patients treated with immunotherapy alone or with chemotherapy, regardless of PD-L1 status.

ClinicalTrials.gov ID: NCT03527108

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates BBT-207, which targets EGFR mutations resistant to current therapies, in patients with advanced NSCLC who have progressed after treatment with third-generation EGFR TKIs such as osimertinib or lazertinib and have specific EGFR mutations. The open-label study aims to evaluate safety, pharmacokinetics, and preliminary efficacy across dose escalation and expansion phases.

ClinicalTrials.gov ID: NCT05920135

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial is evaluating the safety and preliminary efficacy of combining sarilumab, an IL-6 receptor antibody, with cemiplimab, an anti-PD1 antibody, in patients with locally advanced or metastatic non-squamous non-small cell lung cancer harboring EGFR or LKB1 mutations, who may have received up to three prior therapies.

ClinicalTrials.gov ID: NCT05704634

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates cabozantinib, an oral tyrosine kinase inhibitor, in adult patients with advanced non-small cell lung cancer exhibiting RET, ROS1, or NTRK fusions, or increased MET or AXL activity, to assess its efficacy in tumor reduction.

ClinicalTrials.gov ID: NCT01639508

A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial involves patients with recurrent, metastatic solid tumors expressing HHLA2, including specific cancers like non-small cell lung carcinoma, who are treated with NPX267, a novel monoclonal antibody targeting KIR3DL3 to reactivate immune responses in tumors.

ClinicalTrials.gov ID: NCT05958199

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the combination of amivantamab, an EGFR-MET bispecific antibody, and docetaxel in patients with metastatic NSCLC lacking oncogenic driver mutations, who have progressed on platinum-based chemotherapy and immune checkpoint inhibitors. The study focuses on determining the recommended Phase 2 dose and assessing the treatment's efficacy.

ClinicalTrials.gov ID: NCT06532032

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the safety and feasibility of combining liver SBRT with the immune checkpoint inhibitor Pembrolizumab, which targets PD-1, in adult patients with metastatic non-small cell lung cancer and liver metastases who are eligible for this immunotherapy.

ClinicalTrials.gov ID: NCT05430009